跳至主要内容
临床试验/RBR-494fyn
RBR-494fyn招募中未知

Randomized controlled trial of Low level laser therapy and magnetotherapy as coadjuvant in Bisphosphonate related osteonecrosis of the jaws treatment

niversidade Nove de Julho0 个研究点开始时间: 2020年4月22日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Intervention

入排标准

性别
Female

入选标准

  • Consent to participate in the study through a Free and Informed Consent Form signed by the patient, female, 60 years of age or older, using oral Alendronate sodium, with weekly doses of 70mg for at least 2 years. continuously for the prevention and or treatment of osteopenia or osteoporosis.
  • Presence of jaw osteonecrosis, in stages 1 or 2, according to the AAOMS classification. Patients who have previously undergone oral cavity surgical procedures, such as dental extractions or implants, performed no more than 6 months prior to the occurrence of osteonecrosis.

排除标准

  • Presence of jaw osteonecrosis at stage 0 or 3, according to AAOMS.
  • Presence of spontaneous osteonecrosis in the jaws.
  • Pathological fractures by osteonecrosis.
  • Use of alendronate for less than two years or discontinued.
  • Need to use synthesis material (plate and screws).
  • Indication of the use of alendronate sodium due to malignant neoplasms, bone metastases, Paget's disease or any indication other than osteoporosis or osteopenia.
  • Patients undergoing head and neck radiotherapy in the last 5 years.
  • Patients undergoing hyperbaric chamber sessions in the last 2 years.
  • Patients with blood dyscrasias, renal failure, liver failure, cardio respiratory failure, immune deficiency, malignant neoplasms, AIDS or septicemia.

研究者

发起方
niversidade Nove de Julho

相似试验

ow level laser therapy and magnetotherapy as... | 临床试验